Catalyst Pharmaceuticals (CPRX) Assets (2010 - 2026)

Catalyst Pharmaceuticals has reported Assets for 17 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 26.27% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 26.27% YoY), and the FY2025 full-year result was $1.1 billion, up 29.66% from the prior year.
• Assets for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Assets was $1.1 billion in Q1 2026, with the low at $247.0 million in Q1 2022.
• Historically, Assets has averaged $654.0 million across 5 years, with a median of $646.7 million in 2024.
• Annual changes were most pronounced in 2023 — Assets rose 24.04% — and 2024, when it soared 86.83%.
• Catalyst Pharmaceuticals' Assets stood at $375.6 million in 2022, then grew by 25.15% to $470.1 million in 2023, then soared by 81.11% to $851.4 million in 2024, then gained by 29.66% to $1.1 billion in 2025, then advanced by 3.95% to $1.1 billion in 2026.
• The last three Assets figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.